deltatrials
Terminated PHASE1 INTERVENTIONAL 1-arm NCT02829372

Phase 1 Study of Single Agent GBR 1302 in Subjects With HER2 Positive Cancers (GBR 1302-101)

A Phase 1, First-in-man, Multicenter, Open-label, Dose-escalation Study of Single-agent GBR 1302 in Subjects With HER2 Positive Cancers

Sponsor: Glenmark Pharmaceuticals S.A.

Conditions HER2 Expressing Solid Tumours
Interventions CD3/HER2 bispecific monoclonal antibody
Updated 14 times since 2017 Last updated: Oct 8, 2020 Started: May 31, 2016 Primary completion: May 31, 2019 Completion: May 31, 2019
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention

This PHASE1 trial investigates HER2 Expressing Solid Tumours and is currently terminated or withdrawn. Glenmark Pharmaceuticals S.A. leads this study, which shows 14 recorded versions since 2016 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Jun 2017 · 5 months · monthly snapshot~Jun 2017 – ~Mar 2018 · 9 months · monthly snapshot~Mar 2018 – ~Apr 2018 · 31 days · monthly snapshot~Apr 2018 – ~Jun 2018 · 2 months · monthly snapshot~Jun 2018 – ~Jan 2019 · 7 months · monthly snapshot~Jan 2019 – ~May 2019 · 4 months · monthly snapshot~May 2019 – ~Jan 2020 · 8 months · monthly snapshot~Jan 2020 – ~Feb 2020 · 31 days · monthly snapshot~Feb 2020 – ~Nov 2020 · 9 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshot~Dec 2021 – ~Jul 2024 · 31 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 19 months · monthly snapshot

Change History

14 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE1

  3. Dec 2021 — Jul 2024 [monthly]

    Terminated PHASE1

  4. Jan 2021 — Dec 2021 [monthly]

    Terminated PHASE1

  5. Nov 2020 — Jan 2021 [monthly]

    Terminated PHASE1

▶ Show 9 earlier versions

  1. Feb 2020 — Nov 2020 [monthly]

    Terminated PHASE1

  2. Jan 2020 — Feb 2020 [monthly]

    Terminated PHASE1

    Status: Active Not Recruiting → Terminated

  3. May 2019 — Jan 2020 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  4. Jan 2019 — May 2019 [monthly]

    Recruiting PHASE1

  5. Jun 2018 — Jan 2019 [monthly]

    Recruiting PHASE1

  6. Apr 2018 — Jun 2018 [monthly]

    Recruiting PHASE1

  7. Mar 2018 — Apr 2018 [monthly]

    Recruiting PHASE1

  8. Jun 2017 — Mar 2018 [monthly]

    Recruiting PHASE1

  9. Jan 2017 — Jun 2017 [monthly]

    Recruiting PHASE1

    First recorded

May 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Glenmark Pharmaceuticals S.A.
  • Ichnos Sciences SA
Data source: Ichnos Sciences SA

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations